swanlinbar Monday, 05/18/20 12:56:35 PM Re: None Post # of 1449 CANF added a few more today for the Long haul Can-Fite BioPharma Up 18.5%; Reports Additional Findings From Phase II Study 7:27 am ET May 18, 2020 (Dow Jones) Print By Michael Dabaie Can-Fite BioPharma Ltd. shares were up 18.5%, to $2.18, in premarket trading. The company Monday unveiled additional findings from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease with or without non-alcoholic steatohepatitis. The company in April reported topline results from the Phase II study indicating Namodenoson had achieved its efficacy endpoints in a dose dependent and statistically significant manner. The company said a more recent in-depth review of the Phase II data showed 25 mg of Namodenoson was found to resolve significantly all cases of NASH, representing 25% of the 25 mg treated group. In the Phase II study, 25 mg of Namodenoson was shown to reduce hepatic fibrosis, or scar tissue in the liver resulting from the liver trying to repair itself, reduce fat buildup in the liver, and improve the FAST score, a measure for NASH, the company said. Write to Michael Dabaie at firstname.lastname@example.org (END) Dow Jones Newswires "that a rich man is not the one who has the most but the one who needs the least"